The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model

  • Received : 2014.10.20
  • Accepted : 2014.12.17
  • Published : 2015.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study is to develop a physiologically based pharmacokinetic (PBPK) model in intra-abdominal infected rats, and extrapolate it to human to predict moxifloxacin pharmacokinetics profiles in various tissues in intra-abdominal infected human. 12 male rats with intra- abdominal infections, induced by Escherichia coli, received a single dose of 40 mg/kg body weight of moxifloxacin. Blood plasma was collected at 5, 10, 20, 30, 60, 120, 240, 480, 1440 min after drug injection. A PBPK model was developed in rats and extrapolated to human using GastroPlus software. The predictions were assessed by comparing predictions and observations. In the plasma concentration versus time profile of moxifloxcinin rats, $C_{max}$ was $11.151{\mu}g/mL$ at 5 min after the intravenous injection and $t_{1/2}$ was 2.936 h. Plasma concentration and kinetics in human were predicted and compared with observed datas. Moxifloxacin penetrated and accumulated with high concentrations in redmarrow, lung, skin, heart, liver, kidney, spleen, muscle tissues in human with intra-abdominal infection. The predicted tissue to plasma concentration ratios in abdominal viscera were between 1.1 and 2.2. When rat plasma concentrations were known, extrapolation of a PBPK model was a method to predict drug pharmacokinetics and penetration in human. Moxifloxacin has a good penetration into liver, kidney, spleen, as well as other tissues in intra-abdominal infected human. Close monitoring are necessary when using moxifloxacin due to its high concentration distribution. This pathological model extrapolation may provide reference to the PK/PD study of antibacterial agents.

Keywords

References

  1. Singh R, Ledesma KR, Chang KT, Hou JG, Prince RA, Tam VH. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother. 2009;64:556-562. https://doi.org/10.1093/jac/dkp247
  2. Kern A, Kanhai W, Frohde R, et al. BAY 12-8039, a new 8-methoxy-quinolone: metabolism in rat, monkey and man [abstract no. F23]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans, Louisiana: 103.
  3. Edginton AN, Ahr G, Willmann S, Stass H. Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2009;48:181-187. https://doi.org/10.2165/00003088-200948030-00004
  4. Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y. Efficacy and safety of moxifloxacin for communityacquired bacterial pneumonia based on pharmacokinetic analysis. J Infect Chemother. 2011;17:678-685. https://doi.org/10.1007/s10156-011-0282-6
  5. Ober MC, Hoppe-Tichy T, Koninger J, Schunter O, Sonntag HG, Weigand MA, Encke J, Gutt C, Swoboda S. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. J Antimicrob Chemother. 2009;64:1091-1095. https://doi.org/10.1093/jac/dkp318
  6. Majcher-Peszynska J, Sass M, Schipper S, Czaika V, Gussmann A, Lobmann R, Mundkowski RG, Luebbert C, Kujath P, Ruf BR, Koch H, Schareck W, Klar E, Drewelow B; Moxifloxacin-DFI Study Group. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. Eur J Clin Pharmacol. 2011;67:135-142. https://doi.org/10.1007/s00228-010-0903-5
  7. Kees MG, Weber S, Kees F, Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother. 2011;66:2330-2335. https://doi.org/10.1093/jac/dkr282
  8. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol. 2002;53:232-237. https://doi.org/10.1046/j.0306-5251.2001.01557.x
  9. Barth J, Jager D, Mundkowski R, Drewelow B, Welte T, Burkhardt O. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. J Antimicrob Chemother. 2008;62:575-578. https://doi.org/10.1093/jac/dkn212
  10. Pletz MW, Bloos F, Burkhardt O, Brunkhorst FM, Bode-Boger SM, Martens-Lobenhoffer J, Greer MW, Stass H, Welte T. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med. 2010;36:979-983. https://doi.org/10.1007/s00134-010-1864-y
  11. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother. 2006;58:693-696. https://doi.org/10.1093/jac/dkl305
  12. Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig. 2008;28:71-79. https://doi.org/10.2165/00044011-200828020-00001
  13. Campbell A. Development of PBPK model of molinate and molinate sulfoxide in rats and humans. Regul Toxicol Pharmacol. 2009;53:195-204. https://doi.org/10.1016/j.yrtph.2009.01.003
  14. Wenli Yu, Naiqiang Cui, Qiang Fu, Donghua Li. Immune imbalance of rats with severe abdominal infection. Chinese Journal of Surgery of Integrated Traditional and Western Medicine 2011;17:276-279.
  15. Poirier A, Funk C, Scherrmann JM, Lave T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm. 2009;6: 1716-1733. https://doi.org/10.1021/mp8002495
  16. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259-1276. https://doi.org/10.1002/jps.20322
  17. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95: 1238-1257. https://doi.org/10.1002/jps.20502
  18. Mannhold R, Poda GI, Ostermann C, Tetko IV. Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds. J Pharm Sci. 2009;98:861-893. https://doi.org/10.1002/jps.21494
  19. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos. 2007;35:649-659. https://doi.org/10.1124/dmd.106.014027
  20. Lee AC, Crippen GM. Predicting pKa. J Chem Inf Model. 2009;49:2013-2033. https://doi.org/10.1021/ci900209w
  21. Senggunprai L, Yoshinari K, Yamazoe Y. Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug Metab Dispos. 2009;37: 1711-1717. https://doi.org/10.1124/dmd.109.027441
  22. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:649-658. https://doi.org/10.1128/AAC.01201-10
  23. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother. 2000;44:798-801. https://doi.org/10.1128/AAC.44.3.798-801.2000
  24. MacGowan AP. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opin Investig Drugs. 1999;8:181-199. https://doi.org/10.1517/13543784.8.2.181
  25. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clinical Drug Investigation. 1999;17:365-387. https://doi.org/10.2165/00044011-199917050-00004
  26. Li GF, Wang K, Chen R, Zhao HR, Yang J, Zheng QS. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol Sin. 2012;33:1359-1371. https://doi.org/10.1038/aps.2012.103
  27. Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006;45:511-542. https://doi.org/10.2165/00003088-200645050-00006
  28. Eichler HG, Muller M. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet. 1998;34:95-99. https://doi.org/10.2165/00003088-199834020-00001
  29. Siefert HM, Kohlsdorfer C, Steinke W, Witt A. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. Journal of Antimicrobial Chemotherapy. 1999;43(Suppl 2):61-67.
  30. Stass H. Distribution and Tissue Penetration of Moxifloxacin. Drugs. 1999;58 Suppl 2:229-230. https://doi.org/10.2165/00003495-199958002-00070
  31. Stass H, Kubitza D, Aydeniz B, Wallwiener D, Halabi A, Gleiter C. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet. 2008;102:132-136. https://doi.org/10.1016/j.ijgo.2008.02.020
  32. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, Towne JB. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. 2004;48:1012-1016. https://doi.org/10.1128/AAC.48.3.1012-1016.2004
  33. Schaumann R, Goldstein EJ, Forberg J, Rodloff AC. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol. 2005;54:749-753. https://doi.org/10.1099/jmm.0.45994-0
  34. Singh VP, Singh N, Jaggi AS. A review on renal toxicity profile of common abusive drugs. Korean J Physiol Pharmacol. 2013;17: 347-357. https://doi.org/10.4196/kjpp.2013.17.4.347
  35. Randhawa PK, Singh K, Singh N, Jaggi AS. A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol. 2014;18:279-288. https://doi.org/10.4196/kjpp.2014.18.4.279
  36. Watson KJ, Gorczyca WP, Umland J, Zhang Y, Chen X, Sun SZ, Fermini B, Holbrook M, Van Der Graaf PH. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. J Pharmacol Toxicol Methods. 2011;63:304-313. https://doi.org/10.1016/j.vascn.2011.03.002
  37. Moxifloxacin. Tuberculosis (Edinb). 2008;88:127-131. https://doi.org/10.1016/S1472-9792(08)70016-7

Cited by

  1. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification vol.43, pp.11, 2015, https://doi.org/10.1124/dmd.115.065920
  2. Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration vol.37, pp.2, 2015, https://doi.org/10.1038/aps.2015.122
  3. Drug–drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats vol.30, pp.10, 2015, https://doi.org/10.1002/bmc.3726
  4. Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults vol.11, pp.10, 2015, https://doi.org/10.1371/journal.pone.0164641
  5. Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK vol.14, pp.2, 2015, https://doi.org/10.2174/1574892814666190212164356
  6. Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen vol.20, pp.1, 2015, https://doi.org/10.1208/s12249-018-1219-5
  7. Involvement of glutamate receptors of the paragigantocellularis lateralis nucleus in the pain modulatory effect of 17β-estradiol in male rats vol.120, pp.3, 2015, https://doi.org/10.1007/s13760-018-0998-5
  8. Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice vol.10, pp.9, 2015, https://doi.org/10.1002/cpdd.941